• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于患者分层的预测性特征开发的PRIM方法。

A PRIM approach to predictive-signature development for patient stratification.

作者信息

Chen Gong, Zhong Hua, Belousov Anton, Devanarayan Viswanath

机构信息

Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center New York, Roche TCRC, Inc., 430 East 29th Street, New York, NY 10016, U.S.A.

出版信息

Stat Med. 2015 Jan 30;34(2):317-42. doi: 10.1002/sim.6343. Epub 2014 Oct 27.

DOI:10.1002/sim.6343
PMID:25345685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4285951/
Abstract

Patients often respond differently to a treatment because of individual heterogeneity. Failures of clinical trials can be substantially reduced if, prior to an investigational treatment, patients are stratified into responders and nonresponders based on biological or demographic characteristics. These characteristics are captured by a predictive signature. In this paper, we propose a procedure to search for predictive signatures based on the approach of patient rule induction method. Specifically, we discuss selection of a proper objective function for the search, present its algorithm, and describe a resampling scheme that can enhance search performance. Through simulations, we characterize conditions under which the procedure works well. To demonstrate practical uses of the procedure, we apply it to two real-world data sets. We also compare the results with those obtained from a recent regression-based approach, Adaptive Index Models, and discuss their respective advantages. In this study, we focus on oncology applications with survival responses.

摘要

由于个体异质性,患者对治疗的反应往往不同。如果在进行试验性治疗之前,根据生物学或人口统计学特征将患者分为反应者和无反应者,临床试验的失败率可以大幅降低。这些特征由一个预测特征来体现。在本文中,我们提出了一种基于患者规则归纳法来搜索预测特征的程序。具体来说,我们讨论了搜索中合适目标函数的选择,给出了其算法,并描述了一种可以提高搜索性能的重采样方案。通过模拟,我们刻画了该程序运行良好的条件。为了证明该程序的实际用途,我们将其应用于两个真实世界的数据集。我们还将结果与最近基于回归的方法——自适应指数模型得到的结果进行比较,并讨论它们各自的优点。在本研究中,我们专注于具有生存反应的肿瘤学应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/fd23f0eac935/sim0034-0317-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/91dc1aa016f4/sim0034-0317-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/242616075ba3/sim0034-0317-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/6912694b8781/sim0034-0317-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/87f7400ed67a/sim0034-0317-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/4cd266c24fd5/sim0034-0317-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/5799901c4326/sim0034-0317-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/d54e81a60d48/sim0034-0317-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/546a1ebddcdf/sim0034-0317-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/fd23f0eac935/sim0034-0317-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/91dc1aa016f4/sim0034-0317-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/242616075ba3/sim0034-0317-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/6912694b8781/sim0034-0317-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/87f7400ed67a/sim0034-0317-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/4cd266c24fd5/sim0034-0317-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/5799901c4326/sim0034-0317-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/d54e81a60d48/sim0034-0317-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/546a1ebddcdf/sim0034-0317-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d2/4285951/fd23f0eac935/sim0034-0317-f8.jpg

相似文献

1
A PRIM approach to predictive-signature development for patient stratification.一种用于患者分层的预测性特征开发的PRIM方法。
Stat Med. 2015 Jan 30;34(2):317-42. doi: 10.1002/sim.6343. Epub 2014 Oct 27.
2
Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.他莫昔芬治疗获益预测特征与早期雌激素受体阳性乳腺癌术后复发风险的预后特征相结合
Oncotarget. 2015 Dec 29;6(42):44593-608. doi: 10.18632/oncotarget.6260.
3
Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.回复:使用微阵列数据预测乳腺癌临床治疗结果模型的局限性
J Natl Cancer Inst. 2005 Dec 21;97(24):1851-2; author reply 1852-3. doi: 10.1093/jnci/dji433.
4
CYP2D6 pharmacogenomics of tamoxifen treatment.他莫昔芬治疗的CYP2D6药物基因组学
Technol Eval Cent Assess Program Exec Summ. 2008 May;23(1):1-4.
5
Breakthrough in ER+ breast cancer. Specific gene's shutdown is detectable in blood; indicates cancer cell vulnerability, thus enabling earlier treatment.雌激素受体阳性(ER+)乳腺癌取得突破。血液中可检测到特定基因的关闭;这表明癌细胞存在脆弱性,从而能够实现更早的治疗。
Duke Med Health News. 2013 Oct;19(10):7.
6
Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.预测雌激素受体阳性乳腺癌组织和血清中他莫昔芬耐药性的靶向质谱分析
J Proteome Res. 2016 Apr 1;15(4):1230-42. doi: 10.1021/acs.jproteome.5b01119. Epub 2016 Mar 18.
7
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.包括雌激素受体(ER)、孕激素受体(PR)、Bcl-2和胰岛素样生长因子-1受体(IGF-IR)在内的雌激素受体活性谱,可能有潜力作为晚期乳腺癌患者来曲唑或他莫昔芬治疗的选择标准。
Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.
8
Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.药理学、药物遗传学和药物流行病学:个体化治疗的三个“P”
Cancer Invest. 2009 Oct;27(8):809-15. doi: 10.1080/07357900903152523.
9
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.一种与原发性乳腺癌中他莫昔芬治疗失败相关的候选分子特征。
Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.
10
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.ADAM-9和ADAM-11与雌激素受体在预测复发乳腺癌患者对他莫昔芬治疗反应方面的差异:一项回顾性研究。
Clin Cancer Res. 2005 Oct 15;11(20):7311-21. doi: 10.1158/1078-0432.CCR-05-0560.

引用本文的文献

1
Toward Precision in Critical Care Research: Methods for Observational and Interventional Studies.迈向重症监护研究的精准化:观察性和干预性研究方法。
Crit Care Med. 2024 Sep 1;52(9):1439-1450. doi: 10.1097/CCM.0000000000006371. Epub 2024 Aug 15.
2
Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review.机器学习模型在预后和预测性癌症生物标志物识别中的应用:系统评价。
Int J Mol Sci. 2023 Apr 24;24(9):7781. doi: 10.3390/ijms24097781.
3
A reference-free R-learner for treatment recommendation.

本文引用的文献

1
Subgroup identification from randomized clinical trial data.随机临床试验数据中的亚组识别。
Stat Med. 2011 Oct 30;30(24):2867-80. doi: 10.1002/sim.4322. Epub 2011 Aug 4.
2
Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations.基于差异效应搜索的亚组识别——一种递归分区方法,用于建立患者亚组对治疗的反应。
Stat Med. 2011 Sep 20;30(21):2601-21. doi: 10.1002/sim.4289. Epub 2011 Jul 22.
3
Adaptive index models for marker-based risk stratification.
一种用于治疗推荐的无参考 R-learner。
Stat Methods Med Res. 2023 Feb;32(2):404-424. doi: 10.1177/09622802221144326. Epub 2022 Dec 20.
4
An Application of the Patient Rule-Induction Method to Detect Clinically Meaningful Subgroups from Failed Phase III Clinical Trials.患者规则归纳法在从失败的III期临床试验中检测具有临床意义亚组中的应用。
Int J Clin Biostat Biom. 2021;7(1). doi: 10.23937/2469-5831/1510038. Epub 2021 Jun 28.
5
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement.预测治疗效果异质性的方法(PATH)声明。
Ann Intern Med. 2020 Jan 7;172(1):35-45. doi: 10.7326/M18-3667. Epub 2019 Nov 12.
6
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.阿达木单抗在中重度化脓性汗腺炎中的中期剂量策略:来自 III 期随机安慰剂对照 PIONEER 试验的综合结果。
Br J Dermatol. 2019 Nov;181(5):967-975. doi: 10.1111/bjd.17919. Epub 2019 Aug 14.
7
Patient subgroup identification for clinical drug development.用于临床药物开发的患者亚组识别
Stat Med. 2017 Apr 30;36(9):1414-1428. doi: 10.1002/sim.7236. Epub 2017 Feb 1.
基于标志物的风险分层的自适应指数模型。
Biostatistics. 2011 Jan;12(1):68-86. doi: 10.1093/biostatistics/kxq047. Epub 2010 Jul 27.
4
Stromal gene signatures in large-B-cell lymphomas.大B细胞淋巴瘤中的基质基因特征
N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.
5
Applying PRIM (Patient Rule Induction Method) and logistic regression for selecting high-risk subgroups in very elderly ICU patients.应用PRIM(患者规则归纳法)和逻辑回归来选择高龄重症监护病房患者中的高危亚组。
Int J Med Inform. 2008 Apr;77(4):272-9. doi: 10.1016/j.ijmedinf.2007.06.007. Epub 2007 Jul 23.
6
An application of the patient rule-induction method for evaluating the contribution of the Apolipoprotein E and Lipoprotein Lipase genes to predicting ischemic heart disease.应用患者规则归纳法评估载脂蛋白E和脂蛋白脂肪酶基因对预测缺血性心脏病的贡献。
Genet Epidemiol. 2007 Sep;31(6):515-27. doi: 10.1002/gepi.20225.
7
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.通过基因组分级定义雌激素受体阳性乳腺癌中临床上不同的分子亚型。
J Clin Oncol. 2007 Apr 1;25(10):1239-46. doi: 10.1200/JCO.2006.07.1522.
8
Pre-validation and inference in microarrays.微阵列中的预验证和推断
Stat Appl Genet Mol Biol. 2002;1:Article1. doi: 10.2202/1544-6115.1000. Epub 2002 Aug 22.
9
Adaptive risk group refinement.适应性风险组细化
Biometrics. 2005 Jun;61(2):370-8. doi: 10.1111/j.1541-0420.2005.020738.x.
10
Statistical methods for analyzing tissue microarray data.分析组织微阵列数据的统计方法。
J Biopharm Stat. 2004 Aug;14(3):671-85. doi: 10.1081/BIP-200025657.